Last $36.11 USD
Change Today +0.11 / 0.31%
Volume 194.4K
PODD On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

9 Oak Park Drive

Bedford, MA 01730

United States

Phone: 781-457-5000

Fax: 781-457-5011

Insulet Corporation develops, manufactures, and sells proprietary OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the commercially available insulin infusion system of its kind. The OmniPod System features a disposable tubeless OmniPod which is worn on the body for approximately three days at a time and its handheld, wireless personal diabetes manager (PDM). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to 42 inches of tubing. The company owns Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, Neighborhood Diabetes) to expand its full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the company provides customers with blood glucose testing supplies, insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits. The company sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The OmniPod system is available in multiple countries in Europe through its exclusive distribution partner, Ypsomed Distribution AG (Ypsomed) and in Canada through its exclusive distribution partner GlaxoSmithKline (GSK). Under these distribution agreements, the company supplies OmniPods and PDMs to Ypsomed and GSK, and they are responsible for the sale to the customer, including distribution, reimbursement and customer support. The OmniPod System The OmniPod System was specifically designed to provide people with insulin-dependent diabetes with a diabetes management solution, which provides significant lifestyle and other benefits and to expand the use of CSII therapy. Discreet, Two-Part Design: The OmniPod System consists of two discreet devices that communicate wirelessly, such as the OmniPod, a disposable insulin infusion device worn beneath clothing that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism and batteries; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions, assists the patient with diabetes management and integrates a blood glucose meter. The OmniPod would operate approximately 72 hours (and not approximately 80 hours) after it is first activated. No Tubing: The OmniPod System’s proprietary design reduces the size of the insulin delivery mechanism, thereby eliminating the need for the external tubing required by conventional pumps. As a result of this design, the OmniPod could be worn discreetly beneath clothing and patients could move, dress, bathe, sleep, and exercise without the encumbrance of approximately 42 inches of tubing required by conventional insulin pumps. Pain-Free Automated Cannula Insertion: The OmniPod is the continuous subcutaneous insulin infusion (CSII) therapy device to feature an automated, hands-free cannula insertion system. This pain-free insertion system features fastest insertion and the smallest-gauge introducer needle available for insulin infusion systems. Easy to Train, Learn, and Use: The company has designed the OmniPod System to fit within the normal daily routines of patients. The OmniPod System requires the fewest steps to start insulin delivery of all CSII therapies on the market by automating much of the process. In addition, the OmniPod System consists of two devices, as opposed to approximately seven for conventional insulin pumps. Low Up-Front Cost and Pay-As-You-Go Pricing Structure: The OmniPod System’s patented design and proprietary manufacturing process have enabled the company to provide CSII therapy at a low up-front investment compared to conventional insulin pumps. Sales and Marketing The company’s sales and marketing effort for the OmniPod System is focused on continuing to generate demand and acceptance

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PODD:US $36.11 USD +0.11

PODD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $117.17 USD +0.69
DexCom Inc $44.20 USD -0.08
Smiths Group PLC 1,316 GBp +2.00
Tandem Diabetes Care Inc $14.15 USD +0.10
Unilife Corp $2.55 USD +0.08
View Industry Companies
 

Industry Analysis

PODD

Industry Average

Valuation PODD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 25.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit www.insulet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.